Clinical Report: Molecular Profiling and Treatment Outcomes in NSCLC
Overview
This study examines molecular testing documentation, treatment patterns, and survival outcomes in metastatic non-small cell lung cancer (NSCLC) within a Colombian registry.
Background
Metastatic non-small cell lung cancer is a leading cause of cancer mortality, with treatment increasingly reliant on identifying actionable oncogenic drivers and PD-L1 expression. Variability in biomarker testing and treatment delivery across health systems can lead to disparities in patient outcomes.
Data Highlights
Parameter
Value
Patients included
585
Mean age
72.0 years
Female patients
52.0%
EGFR/ALK altered
32.8%
First-line therapy: Chemotherapy alone
34.4%
First-line therapy: Chemo-immunotherapy
21.0%
Overall survival median follow-up
34.99 months
Key Findings
32.8% of patients had EGFR/ALK alterations.
First-line treatments included chemotherapy alone (34.4%) and targeted therapy (26.7%).
PD-L1 expression was <1% in 25.5% of patients.
Higher mortality was associated with not tested/unknown driver status (hazard ratio 2.26).
Age and ECOG performance status were significant predictors of mortality.
Clinical Implications
The findings highlight the need for improved molecular testing and documentation practices in metastatic NSCLC to enhance treatment selection and patient outcomes. Addressing barriers in healthcare delivery is essential for optimizing care in this population.
Conclusion
This study highlights challenges related to incomplete molecular characterization and treatment documentation in metastatic NSCLC within a Colombian context.
by Ricardo Brugés, Pedro Ramos, Milton Lombana, Anderson Osma, Néstor Llinás, Javier Cuello, Andrés Yepes, Ray Manneh, Anabelly Coronel, Rebeca Granadillo, Carolina López, Álvaro Osorio, Daniel Santa, Natalia Arango, William Mantilla, Diego Gómez
